Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 1
---
    Operating lease liability, net of current portion 
     274,074  
     342,098 
  
    Finance lease liability, net of current portion 
     3,942  
     444,448 
  
    Notes payable, net of current portion 
     45,952  
     20,180 
  
    Warrant liability 
     3,974,911  
     — 

    Total liabilities 
     6,887,183  
     3,911,631 

    Commitments and contingencies (Note 11) 
     -  
     - 

    Stockholders’ equity (deficit): 

    Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at June 30, 2025, and December 31, 2024 
     —  
     — 
  
    Common stock, par value $0.007 per share; 100,000,000 shares authorized; 28,459,541 and 15,576,674 issued and outstanding at June 30, 2025, and December 31, 2024, respectively 
     197,236  
     106,593 
  
    Additional paid-in capital 
     58,032,170  
     56,139,753 
  
    Accumulated deficit 
     (60,365,514) 
     (53,644,310)

    Total stockholders’ equity (deficit) 
     (2,136,108) 
     2,602,036 

    Total liabilities and stockholders’ equity (deficit) 
    $4,751,075  
    $6,513,667 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

5

bioAffinity
Technologies, Inc.

Unaudited
Consolidated Statements of Operations

    Three Months Ended  June 30,  
    Six Months Ended  June 30, 

    2025  
    2024  
    2025  
    2024 

    Net revenue 
    $1,269,483  
    $2,397,652  
    $3,123,080  
    $4,804,043 

    Operating expenses: